|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scholz HS, Tasdemir H, Hunlich T, Turnwald
W, Both A and Egger H: Multivisceral cytoreductive surgery in FIGO
stages IIIC and IV epithelial ovarian cancer: Results and 5-year
follow-up. Gynecol Oncol. 106:591–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buys SS, Partridge E, Black A, Johnson CC,
Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B,
et al: PLCO Project Team: Effect of screening on ovarian cancer
mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Randomized Controlled Trial. JAMA. 305:2295–2303. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen J, Stass SA and Jiang F: MicroRNAs as
potential biomarkers in human solid tumors. Cancer Lett.
329:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
|
|
6
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bendoraite A, Knouf EC, Garg KS, Parkin
RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY,
Drescher CW, et al: Regulation of miR-200 family microRNAs and ZEB
transcription factors in ovarian cancer: Evidence supporting a
mesothelial-to-epithelial transition. Gynecol Oncol. 116:117–125.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SW, Kim JW, Kim YT, Kim JH, Kim S,
Yoon BS, Nam EJ and Kim HY: Analysis of chromosomal changes in
serous ovarian carcinoma using high-resolution array comparative
genomic hybridization: Potential predictive markers of
chemoresistant disease. Genes Chromosomes Cancer. 46:1–9. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zuberi M, Mir R, Das J, Ahmad I, Javid J,
Yadav P, Masroor M, Ahmad S, Ray PC and Saxena A: Expression of
serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in
epithelial ovarian cancer and their association with
clinicopathological features. Clin Transl Oncol. 17:779–787. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li L, Huang K, You Y, Fu X, Hu L, Song L
and Meng Y: Hypoxia-induced miR-210 in epithelial ovarian cancer
enhances cancer cell viability via promoting proliferation and
inhibiting apoptosis. Int J Oncol. 44:2111–2120. 2014.PubMed/NCBI
|
|
11
|
Chen Y, Chen Q, Liu Q and Gao F: Human
epididymis protein 4 expression positively correlated with miR-21
and served as a prognostic indicator in ovarian cancer. Tumour
Biol. 37:8359–8365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Häusler SF, Keller A, Chandran PA, Ziegler
K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler
M, et al: Whole blood-derived miRNA profiles as potential new tools
for ovarian cancer screening. Br J Cancer. 103:693–700. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malentacchi F, Pizzamiglio S, Wyrich R,
Verderio P, Ciniselli C, Pazzagli M and Gelmini S: Effects of
Transport and Storage Conditions on Gene Expression in Blood
Samples. Biopreserv Biobank. 14:122–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al: Cancer
genome atlas research network: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
